<DOC>
	<DOCNO>NCT00084370</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . The use celecoxib prophylactic oophorectomy may effective way prevent development ovarian epithelial cancer . PURPOSE : A controlled pilot trial study effectiveness celecoxib prevent cancer patient high-risk ovarian epithelial cancer undergo prophylactic oophorectomy .</brief_summary>
	<brief_title>Celecoxib Preventing Cancer Patients High Risk Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare histologic molecular alteration tissue biomarkers patient high risk ovarian cancer treat celecoxib follow prophylactic oophorectomy v prophylactic oophorectomy . Secondary - Compare alteration gene expression pattern patient treat regimen . OUTLINE : This pilot study . Patients assign 1 2 treatment group . - Group I : Patients receive oral celecoxib twice daily 3 month undergo prophylactic oophorectomy . - Group II : Patients undergo immediate prophylactic oophorectomy .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : At high risk ovarian cancer meet criteria 1 following : Family history least 2 ovarian** breast cancers* among patient first seconddegree relative lineage Multiple primary cancer person may fulfill requirement Ashkenazi Jewish ethnicity AND 1 firstdegree 2 seconddegree relative breast* ovarian** cancer Ashkenazi Jewish ethnicity AND prior breast cancer* BRCA1/BRCA2 mutation probability &gt; 20 % BRCAPRO Positive BRCA1 BRCA2 mutation First seconddegree relative BRCA1/BRCA2 mutation NOTE : *At least 1 breast cancer must premenopausal ( diagnose age 50 menopausal status unknown ) ; ductal carcinoma situ qualifies breast cancer NOTE : **In relative , ovarian epithelial cancer , fallopian tube cancer , primary papillary serous cancer qualifies ovarian cancer No prior concurrent ovarian cancer , include low malignant potential cancer primary papillary serous carcinoma peritoneum No clinical evidence ovarian cancer physical examination , CA 125 evaluation , pelvic ultrasound PATIENT CHARACTERISTICS : Age 19 Performance status GOG 01 Life expectancy Not specify Hematopoietic WBC &gt; 3,000/mm^3 Granulocyte count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 No hemophilia bleed disorder No serious anemia Hepatic Transaminases normal Bilirubin normal Renal Creatinine clearance &gt; 80 mL/min OR Creatinine &lt; 2.0 mg/dL Pulmonary No emphysema Other Not pregnant nursing No psychiatric psychological condition would preclude give informed consent No concurrent untreated malignancy except nonmelanoma skin cancer No medical condition would preclude blood draw ( e.g. , chronic infectious disease ) PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 3 month since prior adjuvant chemotherapy Endocrine therapy Concurrent adjuvant hormonal therapy ( e.g. , tamoxifen , leuprolide , goserelin ) allow Radiotherapy More 3 month since prior adjuvant radiotherapy Surgery More 3 month since prior intraperitoneal surgery ( laparoscopy laparotomy ) No prior oophorectomy Other More 5 year since prior treatment ( exclude hormonal therapy ) metastatic malignancy No concurrent participation ovarian cancer early detection clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>ovarian epithelial cancer</keyword>
	<keyword>BRCA1 mutation carrier</keyword>
	<keyword>BRCA2 mutation carrier</keyword>
</DOC>